Cationic lipid-conjugated hydrocortisone as selective antitumor agent

Area of Science:

• Oncology
• Pharmacology
• Biochemistry

Background:

• Hydrocortisone is a natural hormone with anti-inflammatory properties but has variable effects in cancer.
• Glucocorticoid receptor (GR) is a key target for steroidal ligands like hydrocortisone.
• Developing targeted therapies with reduced side effects is crucial in cancer treatment.

Purpose of the Study:

• To synthesize and evaluate a novel hydrocortisone conjugate, HYC16, for selective anti-cancer activity.
• To investigate the mechanism of action of HYC16 in cancer cells.
• To assess the in vivo efficacy and anti-angiogenic properties of HYC16.

Main Methods:

• Synthesis of HYC16, a conjugate of hydrocortisone and a C16-alkyl chain cationic lipid.
• In vitro evaluation of HYC16's cytotoxicity in various cancer cell lines (melanoma, breast, lung) and normal cells.
• Analysis of apoptosis induction and cell cycle arrest (G2/M phase) via flow cytometry and other assays.
• In vivo studies using a syngeneic melanoma tumor model to assess tumor growth inhibition and anti-angiogenic effects.

Main Results:

• HYC16 exhibited selective toxicity towards cancer cells, including melanoma, breast cancer, and lung adenocarcinoma, with minimal impact on normal cells.
• Apoptosis induction and G2/M cell cycle arrest were identified as key mechanisms of HYC16's action.
• Significant tumor growth inhibition was observed in vivo, accompanied by increased apoptosis in tumor-associated cells.
• HYC16 demonstrated superior anti-angiogenic activity compared to hydrocortisone, contributing to effective tumor shrinkage.

Conclusions:

• HYC16 represents a novel, selectively cytotoxic agent derived from hydrocortisone.
• The conjugate effectively inhibits tumor growth and angiogenesis, offering a promising therapeutic strategy.
• This work establishes a new approach to repurpose natural hormones into targeted anti-cancer drugs.